Comparison of dexamethasone and Anti-D Immune globulin for immune thrombocytopenia purpura in children

سال انتشار: 1393
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 364

فایل این مقاله در 5 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_RCM-1-2_005

تاریخ نمایه سازی: 2 دی 1398

چکیده مقاله:

Different therapeutic options in children with immune thrombocytopenic purpura include observation alone, periodic treatment with corticosteroids, intravenous immunoglobulin (IVIG) or anti-D, chronic administration of immunosuppressive agents, and splenectomy.Preference of the type of therapy depends on the degree of thrombocytopenia and clinical bleeding manifestations. Dexamethasone is safe but its side effects are the main disadvantages for its usage. Anti-D is more expensive than dexamethason but the side effect is rare and not dangerous and response to treatment is assessed in approximately 3 days after infusion.

کلیدواژه ها:

Children ، Dexamethasone ، Immune thrombocytopenic purpura (ITP)

نویسندگان

Abdollah Banihashem

Department of Pediatrics, School of Medicine, Dr Sheikh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Hamid Farhangi

Department of Pediatrics, School of Medicine, Dr Sheikh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Mojtaba Mousavi Bazaz

Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Zahra Badiee

Department of Pediatrics, School of Medicine, Dr Sheikh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Zimmerman SA, Malinoski FJ, Ware RE. Immunologic Effects of Anti-D ...
  • El Alfy MS, Mokhtar GM, El-Laboudy MA. Randomized trial of ...
  • Shahgholi E, Vosough P, Sotoudeh K, et al. Intravenous immune ...
  • Neunert CE, Bright BC, Buchanan GR. Severe chronic refractory immune ...
  • Despotovic JM, Lambert MP, Herman JH. RhIG for the treatment ...
  • Becker T, Kuenzlen E, Salama A, et  al. Treatment of ...
  • Blanchette V, Imbach P, Andrew M, et al. Randomised trial ...
  • Borgna-Pignatti C, Battisti L, Zecca M, et al. Treatment of ...
  • El Alfy MS, Mokhtar GM, El-Laboudy MA, et al. Randomized ...
  • Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D ...
  • Tarantino MD, Madden RM, Fennewald DL, et al. Treatment of ...
  • Kjaersgaard M, Hasle H. A Review of Anti-D Treatment of ...
  • Caglayan S, Aksit S, Yaprak I, et al. Steroid-free interval ...
  • Yaprak I, Caglayan S, Kansoy S, et al. Long-term use ...
  • Freiberg A, Mauger D. Efficacy, safety, and dose response of ...
  • Moser AM, Shalev H, Kapelushnik J. Anti-D exerts a very ...
  • Newman GC, Novoa MV, Fodero EM, et al. A dose ...
  • Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed ...
  • Ku¨hne T, Freedman J, Semple JW, et al. Platelet and ...
  • Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D ...
  • Trebo MM, Frey E, Gadner H, et al. Subcutaneous anti-D ...
  • De Mattia D, Del Vecchio GC, Russo G, et al. ...
  • Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic ...
  • نمایش کامل مراجع